Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infection
TLR4拮抗剂FP12作为靶向HMGB1/MD-2/TLR4轴治疗致命性流感感染的先导药物,正在进行临床前开发。
期刊:Innate Immunity
影响因子:2.8
doi:10.1177/17534259241313201
Shirey, Kari Ann; Romerio, Alessio; Shaik, Mohammed Monsoor; Leake, David S; Palmer, Charys; Skupinska, Natalia; Paton, Jules; Pirianov, Grisha; Blanco, Jorge Cg; Vogel, Stefanie N; Peri, Francesco